Logo image of ATNF

180 LIFE SCIENCES CORP (ATNF) Stock Fundamental Analysis

NASDAQ:ATNF - Nasdaq - US68236V3024 - Common Stock - Currency: USD

1.33  +0.44 (+49.44%)

Premarket: 1.25 -0.08 (-6.02%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ATNF. ATNF was compared to 566 industry peers in the Biotechnology industry. ATNF has a bad profitability rating. Also its financial health evaluation is rather negative. ATNF does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ATNF has reported negative net income.
ATNF had a negative operating cash flow in the past year.
ATNF had negative earnings in each of the past 5 years.
In the past 5 years ATNF always reported negative operating cash flow.
ATNF Yearly Net Income VS EBIT VS OCF VS FCFATNF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

ATNF's Return On Assets of -111.10% is on the low side compared to the rest of the industry. ATNF is outperformed by 79.15% of its industry peers.
Looking at the Return On Equity, with a value of -153.26%, ATNF is doing worse than 64.49% of the companies in the same industry.
Industry RankSector Rank
ROA -111.1%
ROE -153.26%
ROIC N/A
ROA(3y)-229.08%
ROA(5y)-148.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATNF Yearly ROA, ROE, ROICATNF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K -5K 10K 15K

1.3 Margins

ATNF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATNF Yearly Profit, Operating, Gross MarginsATNF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, ATNF has more shares outstanding
Compared to 5 years ago, ATNF has more shares outstanding
The debt/assets ratio for ATNF has been reduced compared to a year ago.
ATNF Yearly Shares OutstandingATNF Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
ATNF Yearly Total Debt VS Total AssetsATNF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -16.13, we must say that ATNF is in the distress zone and has some risk of bankruptcy.
ATNF has a worse Altman-Z score (-16.13) than 82.51% of its industry peers.
ATNF has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, ATNF is in line with its industry, outperforming 48.94% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.13
ROIC/WACCN/A
WACCN/A
ATNF Yearly LT Debt VS Equity VS FCFATNF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 1.47 indicates that ATNF should not have too much problems paying its short term obligations.
With a Current ratio value of 1.47, ATNF is not doing good in the industry: 82.86% of the companies in the same industry are doing better.
ATNF has a Quick Ratio of 1.47. This is a normal value and indicates that ATNF is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.47, ATNF is not doing good in the industry: 81.98% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.47
ATNF Yearly Current Assets VS Current LiabilitesATNF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

ATNF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 78.96%, which is quite impressive.
EPS 1Y (TTM)78.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-455.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to grow by 80.13% on average over the next years. This is a very strong growth
EPS Next Y0%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year54.15%
Revenue Next 2Y91.35%
Revenue Next 3Y90.65%
Revenue Next 5Y80.13%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
ATNF Yearly Revenue VS EstimatesATNF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
ATNF Yearly EPS VS EstimatesATNF Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -100 -200 -300

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATNF. In the last year negative earnings were reported.
Also next year ATNF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATNF Price Earnings VS Forward Price EarningsATNF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATNF Per share dataATNF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ATNF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

180 LIFE SCIENCES CORP

NASDAQ:ATNF (5/1/2025, 8:45:52 PM)

Premarket: 1.25 -0.08 (-6.02%)

1.33

+0.44 (+49.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31 2025-03-31/amc
Earnings (Next)05-13 2025-05-13
Inst Owners16.4%
Inst Owner Change0%
Ins Owners2.47%
Ins Owner Change67.11%
Market Cap5.15M
Analysts82.86
Price TargetN/A
Short Float %6.06%
Short Ratio1.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 3.16
EV/EBITDA N/A
EPS(TTM)-13.47
EYN/A
EPS(NY)-3.06
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS0
BVpS2.39
TBVpS0.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -111.1%
ROE -153.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-229.08%
ROA(5y)-148.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.47
Altman-Z -16.13
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-455.84%
EPS Next Y0%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year54.15%
Revenue Next 2Y91.35%
Revenue Next 3Y90.65%
Revenue Next 5Y80.13%
EBIT growth 1Y53.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y86.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.44%
OCF growth 3YN/A
OCF growth 5YN/A